Subscribe
phillip-minnis-shutterstock-com
Phillip Minnis / Shutterstock.com (High Court of Australia, pictured)
7 October 2015Asia-Pacific

D’Arcy v Myriad: Australia’s High Court deals blow to natural product patents

Australia’s highest court has said that naturally occurring nucleic acid molecules are not patentable, overturning a lower court ruling.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
Australia’s highest court sets date for Myriad hearing
11 June 2015   The High Court of Australia has revealed it will hear oral arguments in the patent dispute between breast cancer survivor Yvonne D’Arcy and molecular diagnostic company Myriad Genetics on June 16 and 17.
Asia-Pacific
Myriad cancer patent upheld in Australia
8 September 2014   Companies in Australia will be able to continue to patent human genes after a court rejected an appeal by a breast cancer survivor.


Editor's picks

Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024

Editor's picks

Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024

More on this story

Asia-Pacific
Australia’s highest court sets date for Myriad hearing
11 June 2015   The High Court of Australia has revealed it will hear oral arguments in the patent dispute between breast cancer survivor Yvonne D’Arcy and molecular diagnostic company Myriad Genetics on June 16 and 17.
Asia-Pacific
Myriad cancer patent upheld in Australia
8 September 2014   Companies in Australia will be able to continue to patent human genes after a court rejected an appeal by a breast cancer survivor.

More on this story

Asia-Pacific
Australia’s highest court sets date for Myriad hearing
11 June 2015   The High Court of Australia has revealed it will hear oral arguments in the patent dispute between breast cancer survivor Yvonne D’Arcy and molecular diagnostic company Myriad Genetics on June 16 and 17.
Asia-Pacific
Myriad cancer patent upheld in Australia
8 September 2014   Companies in Australia will be able to continue to patent human genes after a court rejected an appeal by a breast cancer survivor.

More features

Court denies Regeneron bid to halt copy of blockbuster eye drug
Interview: Klaus Grabinski, UPC Court of Appeal president
Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts